GLP-1 agonists have been the most consequential development in metabolic medicine in at least a decade. Originally developed for type 2 diabetes, these drugs now have meaningful indications for weight management and cardiovascular risk reduction as well. The clinical impact is real. The marketing has outpaced the evidence in places, and the side-effect profile is worth understanding before starting. Here's a clinical view of where they fit.
How they work
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after meals. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. In type 2 diabetes, GLP-1 signaling is diminished, which contributes to the blood sugar problem.
The GLP-1 agonists are synthetic versions that do what the natural hormone does, more potently and for longer. That combination, better insulin response plus delayed stomach emptying plus reduced appetite, is why they work for both diabetes and weight.
The drugs currently in use
| Drug | Brand names | Dosing |
|---|---|---|
| Exenatide | Byetta, Bydureon | Twice daily / weekly |
| Liraglutide | Victoza, Saxenda | Daily |
| Dulaglutide | Trulicity | Weekly |
| Semaglutide | Ozempic, Wegovy, Rybelsus | Weekly injection / daily oral |
| Tirzepatide | Mounjaro, Zepbound | Weekly |
Tirzepatide is technically a dual GIP/GLP-1 agonist, not a pure GLP-1. In practice it tends to produce the most weight loss of the class.
A brief history
The biology of GLP-1 was worked out in the 1990s. The first drug in the class, exenatide, was approved for diabetes in 2005. Longer-acting versions followed through the 2010s. Semaglutide (Ozempic) came to market for diabetes in 2017 and, under the Wegovy brand, for weight loss in 2021. Tirzepatide followed in 2022. The pattern has been steady improvement in efficacy and dosing convenience.
What they're actually used for
Type 2 diabetes
Meaningful A1C reduction. Comparable to or better than most non-insulin options, with the added benefits of weight loss rather than weight gain and low risk of hypoglycemia. For patients with type 2 diabetes who also have atherosclerotic cardiovascular disease, some GLP-1 agonists have clear data for reducing major cardiovascular events, which puts them high on the treatment algorithm.
Obesity and weight management
Liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) are FDA-approved for weight loss. Average weight loss varies by drug: liraglutide around 5 to 8 percent, semaglutide around 12 to 15 percent, tirzepatide 15 to 20 percent or more, based on trial data. Individual response varies.
Weight loss from these drugs reduces risk of diabetes, hypertension, sleep apnea, certain cancers, osteoarthritis progression, and fatty liver disease. It also often improves mood, sleep, and function.
Cardiovascular protection
Independent of weight and glucose effects, some drugs in this class (semaglutide and liraglutide in particular) have data showing reduced risk of heart attack, stroke, and cardiovascular death in high-risk populations. This isn't a marketing claim; it's outcomes data.
Side effects and who shouldn't take them
Most common: nausea, vomiting, diarrhea, constipation, abdominal discomfort. These are usually worst in the first few weeks after starting or after each dose increase and tend to ease over time. Slow titration helps significantly.
Less common but worth knowing: gallbladder issues, pancreatitis (rare), delayed gastric emptying that matters for anesthesia (let your anesthesiologist know), injection-site reactions.
Contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2). Caution in active pancreatitis or severe gastroparesis.
Pregnancy: not appropriate during pregnancy or while attempting pregnancy. Stop well before trying to conceive.
How I think about these drugs in practice
For most patients with type 2 diabetes, GLP-1 agonists belong in the conversation early, not as a last resort. For patients with both diabetes and cardiovascular disease, they often move to the top of the list.
For patients with obesity and without diabetes, the drugs work, but the math is more complicated. They're expensive, insurance coverage varies, and stopping the drug usually leads to significant weight regain, so the implicit decision is often a long-term commitment. I think about them alongside lifestyle work, sleep, and metabolic testing rather than as a replacement for those conversations.
Dosing titration matters. Starting low and going up slowly reduces side effects and keeps patients on the medication long enough to benefit. Patients who stop after two weeks of nausea rarely had a chance to see the drug work.
Duration
For diabetes, typically long-term as part of overall management. For weight, the realistic framing is that these drugs work by addressing the biology of appetite and satiety; that biology doesn't go away when you stop the drug. Most patients who stop regain weight. Treatment is usually continued to maintain the result, though for some patients titrating down or using lower maintenance doses is a reasonable strategy.
The point
GLP-1 agonists are one of the more significant clinical developments I've seen in internal medicine. Used thoughtfully, in the right patients, with appropriate dosing and monitoring, they change outcomes that previously were hard to change. The popular hype glosses over the side effects, the cost, the duration of treatment, and the patient selection. In a real clinical setting, all of those matter.
If you're considering a GLP-1 for diabetes, weight, or cardiovascular risk reduction, it's worth a real conversation with a physician who has the time to walk through whether it's the right tool, which drug, what the dosing plan looks like, and how you'll be monitored. Reach out if you want to talk through your specific situation.
This post is educational and not medical advice. Any medication decision should involve an in-person conversation with your physician.
